Dexrazoxane 250 mg/1

Dexrazoxane 250 mg/1 is a lyophilized powder for solution, used primarily in medical settings. This injectable form is designed for intravenous administration and is manufactured by Hikma Pharmaceuticals USA Inc.

Dexrazoxane is commonly used in conjunction with certain chemotherapy treatments. It is often administered to reduce the risk of cardiac toxicity associated with specific cancer therapies. The primary use of Dexrazoxane is to protect the heart from damage that can occur during chemotherapy, particularly with anthracycline-based treatments.

When administered as directed, Dexrazoxane may help mitigate the cardiotoxic effects of certain chemotherapy drugs. Patients should be monitored for any adverse reactions, as individual responses to the medication can vary. Common effects may include localized reactions at the injection site.

Dexrazoxane should be handled and administered by healthcare professionals in a controlled medical environment. It is important to follow proper storage and preparation guidelines to maintain the integrity of the lyophilized powder. Patients with known allergies to any components of Dexrazoxane should avoid its use.

Dexrazoxane may interact with other medications, particularly those metabolized by the liver. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy and safety of Dexrazoxane.